Since patients treated with a combination of BRAF + MEK inhibitors had better TTR than those treated with anti-PD-1 inhibitors, non-acral types with higher BRAF mutation were preferred for the combination therapy, while acral melanoma with lower BRAF mutation received anti-PD-1 inhibitors. The gene discussed is TTR; the disease is acral lentiginous melanoma.